Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
This clinical trial is testing a powerful mix of chemotherapy and other cancer-fighting medications for adults and teenagers whose leukemia or lymphoma has returned or stopped responding to standard treatments. The goal is to see how well this specific combination works to stop cancer growth while keeping track of any side effects.
You may be able to join if you are over 15 years old and have certain types of fast-growing blood cancers or lymph system cancers that have come back or did not respond to previous treatments. However, you cannot join if you have severe nerve damage, certain active infections like hepatitis B or C, or if you are currently breastfeeding.
Participants will receive a combination of several different medications, including chemotherapy drugs, steroids, and targeted therapies, designed to attack cancer cells in multiple ways. Your health care team will closely monitor you for side effects and check how your body responds to the treatment throughout the study.
This study is currently recruiting participants in Houston, Texas, United States. Your medical team can help you figure out if travel is needed and what schedule to expect.
- 1Tests a combination of medications for hard-to-treat blood and lymph cancers
- 2Open to patients over 15 years old whose cancer has returned or not responded to past treatments
- 3Currently recruiting patients in Houston, Texas
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.